Inventor · disambiguated record
Robert A. Mantei
Also filed as: MANTEI ROBERT · MANTEI ROBERT A
28 granted patents·25 pending applications·588 citations·filing 1991–2024
97Inventor score
Top patents by PatentIndex Score
53 records- 0198US8546399B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesBRUNCKO MILAN·Filed 2010·Granted Oct 1, 2013·100 cites·24 claims
- 0297US9174982B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted Nov 3, 2015·38 cites·7 claims
- 0397US8586754B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2010·Granted Nov 19, 2013·59 cites·8 claims
- 0497US8580794B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDOHERTY GEORGE A·Filed 2010·Granted Nov 12, 2013·44 cites·3 claims
- 0597US8563735B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesBRUNCKO MILAN·Filed 2009·Granted Oct 22, 2013·72 cites·4 claims
- 0697US8557983B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesDOHERTY GEORGE A·Filed 2010·Granted Oct 15, 2013·44 cites·2 claims
- 0796US9034875B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted May 19, 2015·19 cites·1 claims
- 0896US9029404B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2013·Granted May 12, 2015·19 cites·1 claims
- 0994US9073855B2BCL-2 selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·2 claims
- 1094US9045420B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jun 2, 2015·11 cites·1 claims
- 1194US7772231B2Substituted pyrazolo[3,4-d]pyrimidines as protein kinase inhibitorsABBOTT LAB·Filed 2006·Granted Aug 10, 2010·68 cites·20 claims
- 1291US9303025B2Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2014·Granted Apr 5, 2016·11 cites·4 claims
- 1390US9072748B2BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Jul 7, 2015·11 cites·10 claims
- 1490US7491718B2Sulfonamides having antiangiogenic and anticancer activityABBOTT LAB·Filed 2003·Granted Feb 17, 2009·35 cites·3 claims
- 1589US9125913B2Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseasesABBVIE INC·Filed 2013·Granted Sep 8, 2015·10 cites·6 claims
- 1688US2025152600A1Bromodomain inhibitorsABBVIE INC·Filed 2024·Application pending·0 cites
- 1787US9296741B2Bromodomain inhibitorsABBVIE INC·Filed 2013·Granted Mar 29, 2016·7 cites·61 claims
- 1886US2025019364A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2024·Application pending·0 cites
- 1983US2024043404A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2023·Application pending·0 cites
- 2082US11897864B2Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2022·Granted Feb 13, 2024·0 cites·27 claims
- 2180US2023158039A1Bromodomain inhibitorsABBVIE INC·Filed 2022·Application pending·0 cites
- 2279US7323570B2Farnesyltransferase inhibitorsABBOTT LAB·Filed 2006·Granted Jan 29, 2008·2 cites·5 claims
- 2378US10035800B2Substituted 1,4,10-triazadibenzo[cd,f]azulenes, substituted 1,4,5,10-tetraazadibenzo[cd,f]azulenes and substituted 1,4,5,7,10-pentaazadibenzo[cd,f]azulenes as bromodomain inhibitorsABBVIE INC·Filed 2014·Granted Jul 31, 2018·3 cites·48 claims
- 2477US9321764B2Dihydro-pyrrolopyridinone inhibitorsABBVIE INC·Filed 2014·Granted Apr 26, 2016·3 cites·25 claims
- 2575US8354422B2Pyrimidine inhibitors of kinase activityABBOTT LAB·Filed 2010·Granted Jan 15, 2013·2 cites·18 claims
- 2675US2022315555A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2021·Application pending·0 cites
- 2775US2021221789A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2020·Application pending·0 cites
- 2874US8486933B2Pyrimidine inhibitors of kinase activityWANG GARY T·Filed 2010·Granted Jul 16, 2013·3 cites·22 claims
- 2973US7211595B2Farnesyltransferase inhibitorsABBOTT LAB·Filed 2001·Granted May 1, 2007·5 cites·34 claims
- 3072US2021236508A1Bromodomain inhibitorsABBVIE INC·Filed 2020·Application pending·0 cites
- 3170US2020231566A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2019·Application pending·0 cites
- 3270US2021070756A1Tetracyclic bromodomain inhibitorsABBVIE INC·Filed 2020·Application pending·0 cites
- 3369US2010160322A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBOTT LAB·Filed 2009·Application pending·0 cites
- 3468US2020291027A1Tetracyclic bromodomain inhibitorsABBVIE INC·Filed 2020·Application pending·0 cites
- 3568US2019119247A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2018·Application pending·0 cites
- 3665US2018296566A1Bromodomain inhibitorsABBVIE INC·Filed 2018·Application pending·0 cites
- 3764US5268374ANon-peptide renin inhibitorsABBOTT LAB·Filed 1991·Granted Dec 7, 1993·8 cites·10 claims
- 3863US7056925B2Urea kinase inhibitorsABBOTT LAB·Filed 2003·Granted Jun 6, 2006·2 cites·20 claims
- 3963US2019389861A1Tetracyclic bromodomain inhibitorsABBVIE INC·Filed 2019·Application pending·0 cites
- 4063US2017158666A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Application pending·0 cites
- 4162US2012190688A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesBRUNCKO MILAN·Filed 2012·Application pending·0 cites
- 4261US9051315B2Imidazopyridines as a novel scaffold for multi-targeted kinase inhibitionBA-MAUNG NWE Y·Filed 2010·Granted Jun 9, 2015·1 cites·4 claims
- 4361US2018251426A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2017·Application pending·0 cites
- 4461US2018298003A1Tetracyclic bromodomain inhibitorsABBVIE INC·Filed 2018·Application pending·0 cites
- 4559US2015329541A1Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2015·Application pending·0 cites
- 4658US2016143916A1Bromodomain inhibitorsABBVIE INC·Filed 2016·Application pending·0 cites
- 4757US2016304451A1Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseasesABBVIE INC·Filed 2016·Application pending·0 cites
- 4848US8067409B2Protein kinase inhibitorsBA-MAUNG NWE Y·Filed 2008·Granted Nov 29, 2011·0 cites·12 claims
- 4944US2016237084A1Dihydro-pyrrolopyridinone inhibitorsABBVIE INC·Filed 2016·Application pending·0 cites
- 5042US2004034038A1Urea kinase inhibitorsFiled 2002·Application pending·0 cites
Showing the top 50 of 53 patent records by PatentIndex Score.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →